KELOWNA, BC, April 28, 2021 /CNW/ – The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to announce that it has submitted an initial application to list its common shares (“Shares”) on the Nasdaq Capital Market (“Nasdaq”).
We have taken a significant step forward in achieving one of our main goals for 2021 by filing our initial application for listing on the Nasdaq on the back of announcing our first acquisition in the US.
Jeff Fallows, President of The Valens Company
We believe that listing in the US will unlock various opportunities to enhance corporate visibility, increase liquidity and broaden overall awareness of The Valens Company to a larger investor base while driving value for our shareholders.
The listing of the Company’s Shares remains subject to the review and approval by Nasdaq of the Company’s listing application and the satisfaction by the Company of all applicable listing, governance and regulatory requirements. In connection therewith, the Company expects to ask shareholders of the Company (“Shareholders”) to approve a consolidation of the Shares at the next annual and special meeting of Shareholders scheduled for May 25, 2021 (the “Shareholder Meeting”). If the share consolidation is approved at the Shareholder Meeting, the Company believes that it will meet the requirements for listing on the Nasdaq shortly thereafter, including Nasdaq’s financial and liquidity requirements. Further details of the proposed share consolidation will be contained in the management information circular of Valens mailed to Shareholders and to be filed shortly on SEDAR at www.sedar.com.
The Company currently expects that Nasdaq will make a decision on the Company’s application by the end of June 2021. The Shares will continue to be listed on the Toronto Stock Exchange (“TSX”) under the symbol “VLNS”. In addition to the Company’s primary listing on the TSX, the Shares will continue to be quoted on the OTCQX until such time as the Shares may be listed on the Nasdaq, if the Company’s listing application is approved.
Valens has retained Stikeman Elliott LLP in Canada and Foley Hoag LLP in the US as legal counsel to advise the Company throughout the application process.
At Valens, it’s Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services across five core technologies, in addition to best-in-class product development, formulation and manufacturing of cannabis consumer packaged goods. The Valens Company’s high-quality products are exclusively formulated for the medical, therapeutic, health and wellness, and recreational consumer segments, and are offered across numerous product formats, including oils, vapes, concentrates, edibles and topicals, as well as pre-rolls, with a focus on next-generation product development and innovation. Its breakthrough patented emulsification technology, SōRSE™ by Valens, converts cannabis oil into water-soluble emulsions for seamless integration into a variety of product formats, allowing for near-perfect dosing, stability, and taste. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through its wholly owned subsidiary Valens Labs Ltd., the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.
